Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 14/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 13/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.57 |
| ▸ | FAP | Q12884 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2578605 | 1.00 | CYP3A4 (0.67) | CYP3A4CYP2D6ADORA2AADORA1FAP | |
| SCHEMBL14969423 | 0.87 | CYP3A4 (0.62) | CYP3A4CYP2D6ADORA2AADORA1FAP | |
| SCHEMBL14969422 | 0.87 | CYP3A4 (0.62) | CYP3A4CYP2D6ADORA2AADORA1FAP | |
| SCHEMBL28394183 | 0.87 | CYP3A4 (0.65) | CYP3A4CYP2D6ADORA2AADORA1FAP | |
| SCHEMBL20302996 | 0.87 | CYP3A4 (0.67) | CYP3A4CYP2D6ADORA2AADORA1FAP | |
| Hydrochloric Acid SCHEMBL19603087 | 0.86 | CYP3A4 (0.66) | CYP3A4CYP2D6ADORA2AADORA1FAP | |
| SCHEMBL29930426 | 0.86 | CYP3A4 (0.66) | CYP3A4CYP2D6ADORA2AADORA1FAP | |
| SCHEMBL28928320 | 0.86 | CYP3A4 (0.66) | CYP3A4CYP2D6ADORA2AADORA1FAP | |
| SCHEMBL19229982 | 0.85 | CYP3A4 (0.65) | CYP3A4CYP2D6ADORA2AADORA1FAP | |
| SCHEMBL22131061 | 0.82 | ADORA2A (0.60) | CYP3A4CYP2D6ADORA2AADORA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046792-B1 | Process for the preparation of tenofovir | MYLAN LAB LTD (IN) | 2015-02-25 | — | — | EP | claimed |
| EP-2462935-B1 | Process for the preparation of tenofovir | LAURUS LABS PRIVATE LTD (IN) | 2015-01-21 | — | — | EP | claimed |
| EP-2780348-A1 | PROCESS FOR THE PREPARATION OF TENOFOVIR | Laurus Labs Private Limited (IN) | 2014-09-24 | — | — | EP | claimed |
| US-8791259-B2 | Process for the preparation of Tenofovir | LAURUS LABS PRIVATE LIMITED (IN) | 2014-07-29 | — | — | US | claimed |
| US-20130165413-A1 | PROCESS FOR THE PREPARATION OF TENOFOVIR | APTUIT LAURUS PRIVATE LIMITED (IN) | 2013-06-27 | — | — | US | claimed |
| WO-2013072745-A1 | PROCESS FOR THE PREPARATION OF TENOFOVIR | LAURUS LABS PRIVATE LIMITED (IN) | 2013-05-23 | — | — | WO | claimed |
| WO-2012081032-A1 | PROCESS FOR THE PREPARATION OF TENOFOVIR | APTUIT LAURUS PRIVATE LIMITED (IN) | 2012-06-21 | — | — | WO | claimed |
| EP-2462935-A1 | Process for the preparation of tenofovir | Laurus Labs Private Limited (IN) | 2012-06-13 | — | — | EP | claimed |
| US-20090286981-A1 | PROCESS FOR THE PREPARTION OF TENOFOVIR | MYLAN LABORATORIES LIMITED (IN) | 2009-11-19 | — | — | US | claimed |
| EP-2046792-A2 | PROCESS FOR THE PREPARATION OF TENOFOVIR | Matrix Laboratories Limited (IN) | 2009-04-15 | — | — | EP | claimed |
| WO-2008007392-A2 | PROCESS FOR THE PREPARATION OF TENOFOVIR | MATRIX LABORATORIES LIMITED (IN) | 2008-01-17 | — | — | WO | claimed |
| CN-113214322-B | Green and environment-friendly preparation method of tenofovir | 山东立新制药有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-215087125-U | Reation kettle on tenofovir production line | 荆门市帅邦化学科技有限公司 | 2021-12-10 | — | — | CN | disclosed |
| CN-215087123-U | Tenofovir preliminary reaction system | 荆门市帅邦化学科技有限公司 | 2021-12-10 | — | — | CN | disclosed |
| CN-214937136-U | Tenofovir accuse temperature production line | 荆门市帅邦化学科技有限公司 | 2021-11-30 | — | — | CN | disclosed |
| US-6043230-A | Use of tenofovir disoproxil fumarate in treatment of HIV | GILEAD SCIENCES, INC. (US) | 2000-03-28 | — | — | US | disclosed |
| US-5977089-A | ORALLY ADMINISTERING TENOFOVIR DERIVATIVES | GILEAD SCIENCES, INC. (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0915894-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1999-05-19 | — | — | EP | disclosed |
| WO-1999005150-A1 | NUCLEOTIDE ANALOG COMPOSITION AND SYNTHESIS METHOD | GILEAD SCIENCES, INC. (US) | 1999-02-04 | — | — | WO | disclosed |
| WO-1998004569-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165413-A1 | PROCESS FOR THE PREPARATION OF TENOFOVIR | SAMHD1, TYMP, DCTPP1 | CYP3A4 103/4885CYP2D6 288/4885ADORA2A 2915/4885 |
| US-20090286981-A1 | PROCESS FOR THE PREPARTION OF TENOFOVIR | SAMHD1, HPRT1, PHPT1 | CYP3A4 78/4885CYP2D6 212/4885ADORA2A 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.